(Q40982052)

25 September 2017

title

Interferon lambda 4 genotypes and resistance-associated variants in patients infected with hepatitis C virus genotypes 1 and 3. (English)

1 reference

25 September 2017

1 reference

10

Stefan Zeuzem

1 reference

25 September 2017

Kai-Henrik Peiffer

1

1 reference

25 September 2017

Lisa Sommer

2

1 reference

25 September 2017

Simone Susser

3

1 reference

25 September 2017

Johannes Vermehren

4

1 reference

25 September 2017

Eva Herrmann

5

1 reference

25 September 2017

Matthias Döring

6

1 reference

25 September 2017

Julia Dietz

7

1 reference

25 September 2017

Dany Perner

8

1 reference

25 September 2017

Caterina Berkowski

9

1 reference

25 September 2017

Christoph Sarrazin

11

1 reference

25 September 2017

language of work or name

English

0 references

publication date

25 September 2015

1 reference

25 September 2017

1 reference

25 September 2017

volume

63

1 reference

25 September 2017

issue

1

1 reference

25 September 2017

page(s)

63-73

1 reference

Global epidemiology and genotype distribution of the hepatitis C virus infection

25 September 2017

cites work

1 reference

Genome-wide association of IL28B with response to pegylated interferon-alpha and ribavirin therapy for chronic hepatitis C

21 January 2018

1 reference

Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance

21 January 2018

1 reference

IL28B is associated with response to chronic hepatitis C interferon-alpha and ribavirin therapy

21 January 2018

1 reference

Genetic variation in IL28B is associated with chronic hepatitis C and treatment failure: a genome-wide association study

21 January 2018

1 reference

21 January 2018

Innate immunity and HCV.

1 reference

A variant upstream of IFNL3 (IL28B) creating a new interferon gene IFNL4 is associated with impaired clearance of hepatitis C virus

21 January 2018

1 reference

IFNL3 polymorphisms predict response to therapy in chronic hepatitis C genotype 2/3 infection

21 January 2018

1 reference

Importance of IL28B gene polymorphisms in hepatitis C virus genotype 2 and 3 infected patients

21 January 2018

1 reference

Meta-analysis: the impact of IL28B polymorphisms on rapid and sustained virological response in HCV-2 and -3 patients.

21 January 2018

1 reference

Boceprevir for previously treated chronic HCV genotype 1 infection

21 January 2018

1 reference

Telaprevir for previously untreated chronic hepatitis C virus infection

21 January 2018

1 reference

Boceprevir for untreated chronic HCV genotype 1 infection

21 January 2018

1 reference

Telaprevir for retreatment of HCV infection

21 January 2018

1 reference

IFNL4-ΔG genotype is associated with slower viral clearance in hepatitis C, genotype-1 patients treated with sofosbuvir and ribavirin

21 January 2018

1 reference

Faldaprevir and deleobuvir for HCV genotype 1 infection.

21 January 2018

1 reference

All-oral daclatasvir plus asunaprevir for hepatitis C virus genotype 1b: a multinational, phase 3, multicohort study

21 January 2018

1 reference

Subgroup differences in response to 8 weeks of ledipasvir/sofosbuvir for chronic hepatitis C

21 January 2018

1 reference

Ledipasvir and sofosbuvir in patients with genotype 1 hepatitis C virus infection and compensated cirrhosis: An integrated safety and efficacy analysis

21 January 2018

1 reference

Predictive value of interferon-lambda gene polymorphisms for treatment response in chronic hepatitis C.

21 January 2018

1 reference

IL28B expression depends on a novel TT/-G polymorphism which improves HCV clearance prediction

21 January 2018

1 reference

Interferon lambda 4 signals via the IFNλ receptor to regulate antiviral activity against HCV and coronaviruses

21 January 2018

1 reference

Replication of hepatitis C virus

21 January 2018

1 reference

Resistance to direct antiviral agents in patients with hepatitis C virus infection

21 January 2018

1 reference

Chemical genetics strategy identifies an HCV NS5A inhibitor with a potent clinical effect

21 January 2018

1 reference

Virology analyses of HCV isolates from genotype 1-infected patients treated with simeprevir plus peginterferon/ribavirin in Phase IIb/III studies.

21 January 2018

1 reference

Multiple ascending dose study of BMS-790052, a nonstructural protein 5A replication complex inhibitor, in patients infected with hepatitis C virus genotype 1.

21 January 2018

1 reference

Rapid decline of viral RNA in hepatitis C patients treated with VX-950: a phase Ib, placebo-controlled, randomized study

21 January 2018

1 reference

Dynamic hepatitis C virus genotypic and phenotypic changes in patients treated with the protease inhibitor telaprevir

21 January 2018

1 reference

Identification and analysis of fitness of resistance mutations against the HCV protease inhibitor SCH 503034.

21 January 2018

1 reference

Replication capacity of minority variants in viral populations can affect the assessment of resistance in HCV chimeric replicon phenotyping assays

21 January 2018

1 reference

Genotypic and phenotypic analysis of variants resistant to hepatitis C virus nonstructural protein 5A replication complex inhibitor BMS-790052 in humans: in vitro and in vivo correlations.

21 January 2018

1 reference

Update on hepatitis C virus resistance to direct-acting antiviral agents

21 January 2018

1 reference

Deep sequencing reveals mutagenic effects of ribavirin during monotherapy of hepatitis C virus genotype 1-infected patients

21 January 2018

1 reference

Evolution of hepatitis C virus quasispecies during repeated treatment with the NS3/4A protease inhibitor telaprevir

21 January 2018

1 reference

Hepatitis C virus variants with decreased sensitivity to direct-acting antivirals (DAAs) were rarely observed in DAA-naive patients prior to treatment

21 January 2018

1 reference

Prevalence of the hepatitis C virus NS3 polymorphism Q80K in genotype 1 patients in the European region

21 January 2018

1 reference

Viral resistance to specifically targeted antiviral therapies for hepatitis C (STAT-Cs).

21 January 2018

1 reference

Deep sequencing analysis of variants resistant to the non-structural 5A inhibitor daclatasvir in patients with genotype 1b hepatitis C virus infection

21 January 2018

1 reference

HLA class I allele associations with HCV genetic variants in patients with chronic HCV genotypes 1a or 1b infection

21 January 2018

1 reference

Prevalence of natural polymorphisms at the HCV NS5A gene associated with resistance to daclatasvir, an NS5A inhibitor

21 January 2018

1 reference

Association between variants in the interferon lambda 4 locus and substitutions in the hepatitis C virus non-structural protein 5A.

21 January 2018

1 reference

The clinical features of patients with a Y93H variant of hepatitis C virus detected by a PCR invader assay

21 January 2018

1 reference

All-oral 12-week treatment with daclatasvir plus sofosbuvir in patients with hepatitis C virus genotype 3 infection: ALLY-3 phase III study

21 January 2018

1 reference

Daclatasvir plus peginterferon alfa and ribavirin for treatment-naive chronic hepatitis C genotype 1 or 4 infection: a randomised study

21 January 2018

1 reference

Ledipasvir and Sofosbuvir for HCV in Patients Coinfected with HIV-1.

21 January 2018

1 reference

Distinct functions of NS5A in hepatitis C virus RNA replication uncovered by studies with the NS5A inhibitor BMS-790052

21 January 2018

1 reference

Replication of subgenomic hepatitis C virus RNAs in a hepatoma cell line

21 January 2018

1 reference

21 January 2018

Identifiers

DOI

10.1002/HEP.28255

1 reference

25 September 2017

1 reference